Elizabeth Pulte

TitleAsst Professor
InstitutionThomas Jefferson University
DepartmentHematology
Address1015 Chestnut Street
Philadelphia PA 19107
Phone215-955-8544
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pulte ED, Norsworthy KJ, Wang Y, Xu Q, Qosa H, Gudi R, Przepiorka D, Fu W, Okusanya OO, Goldberg KB, De Claro RA, Farrell AT, Pazdur R. FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation. Clin Cancer Res. 2021 Feb 25. PMID: 33632926.
      Citations:    
    2. Pulte ED, Wroblewski T, Bloomquist E, Tang S, Farrell A, Deisseroth A, McKee AE, Pazdur R. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. Oncologist. 2019 Apr 24. PMID: 31019020.
      Citations:    
    3. Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, McKee AE, Pazdur R. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. Oncologist. 2018 Nov; 23(11):1366-1371. PMID: 30018129.
      Citations:    
    4. Pulte ED, Dmytrijuk A, Nie L, Goldberg KB, McKee AE, Farrell AT, Pazdur R. FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. Oncologist. 2018 Feb 07. PMID: 29438096.
      Citations:    
    5. Pulte ED, Nie L, Gormley N, Goldberg KB, McKee A, Farrell A, Pazdur R. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2018 Jan 23; 2(2):116-119. PMID: 29365319.
      Citations:    
    6. Rizk S, Pulte ED, Axelrod D, Ballas SK. Perinatal Maternal Mortality in Sickle Cell Anemia: Two Case Reports and Review of the Literature. Hemoglobin. 2017 Jul - Nov; 41(4-6):225-229. PMID: 29182088.
      Citations:    
    7. Ballas SK, Pulte ED, Lobo C, Riddick-Burden G. Case series of octogenarians with sickle cell disease. Blood. 2016 Oct 4. PMID: 27702797.
      Citations:    
    8. Truong H, Counsilman MJ, Gooptu M, Pulte E, Prestipino AJ, Lallas CD. Orbital Compartment Syndrome as the Presenting Sign of Disseminated Intravascular Coagulation From Metastatic Prostatic Cancer to the Orbit. Urology. 2015 Aug; 86(2):e7-8. PMID: 26165617.
      Citations:    
    9. Pulte ED, McKenzie SE, Caro J, Ballas SK. Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. Hemoglobin. 2014; 38(6):385-9. PMID: 25405915.
      Citations:    
    Co-Authors (5)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _